| 000 | 01429nam a22001937a 4500 | ||
|---|---|---|---|
| 005 | 20250422093431.0 | ||
| 008 | 250422b ph ||||| |||| 00| 0 eng d | ||
| 022 | _a0279-3695 | ||
| 040 | _cOCT | ||
| 100 | _a Kverno , Karan | ||
| 240 |
_aJournal of Psychosocial Nursing and mental health services / _hNovember 2024 |
||
| 245 |
_aZuranolone : _bA rapidly acting oral neuroactive steroid antidepressant for the treatment of postpartum depression / _cKaran Kverno and Fatima Ramos-Marcuse |
||
| 300 |
_aVol 62 (11) Pages 7- 10 : _billustrations ; _c27 cm |
||
| 500 | _aABSTRACT Severe depression, anxiety, and mood dysregulation during pregnancy and postpartum are risk factors for the safety and health of mother and baby. Current best practice guidelines recommend screening for depressive and anxiety symptoms before and during pregnancy, in addition to the postpartum period. Rapid identification and treatment of depression has the potential to be life-saving and prevent deleterious consequences, including impaired mother-infant bonding, emotional dysregulation, and other developmental problems. The current article reviews the neurobiological mechanisms of postpartum depression and a novel rapidly acting oral pharmacotherapeutic neuroactive ste-roid, zuranolone. | ||
| 650 | _aoral neuroactive steroid antidepressant | ||
| 650 | _apostpartum depression | ||
| 700 | _a Ramos-Marcuse, Fatima | ||
| 942 |
_2ddc _cCR _n0 |
||
| 999 |
_c10345 _d10345 |
||